Compare TNC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | NVCR |
|---|---|---|
| Founded | 1870 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.5B |
| IPO Year | 1994 | 2015 |
| Metric | TNC | NVCR |
|---|---|---|
| Price | $69.97 | $10.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $79.00 | $28.08 |
| AVG Volume (30 Days) | 284.6K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,137,600,000.00 | $655,353,000.00 |
| Revenue This Year | $5.44 | $7.72 |
| Revenue Next Year | $5.28 | $6.74 |
| P/E Ratio | $29.61 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $60.18 | $9.82 |
| 52 Week High | $85.91 | $20.05 |
| Indicator | TNC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 39.56 |
| Support Level | $68.77 | N/A |
| Resistance Level | $84.24 | $13.59 |
| Average True Range (ATR) | 2.22 | 0.57 |
| MACD | 0.96 | -0.14 |
| Stochastic Oscillator | 95.49 | 19.73 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.